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Macrophage Infiltration of Tumor Cell Islets Predicts Good 
Prognosis of Lung Cancer
Liu, Lun Xu; Yu, Nan Bin 
Dept. of Thoracic Surgery,West China Hospital,Sichuan University, 
Chengdu, China
Many studies have suggested that the immune inﬁltrate may beneﬁt 
the tumor by producing a pro-tumor microenvironment.The aim of this 
study is to investigate the macrophage inﬁltration in lung cancer and 
benign lesions, and to evaluate its correlation with cancer prognosis.
Methods: Surgically rescected 146 cases of lung cancer and 20 cases 
of benign lesions were examined by immunohistochemical SP method 
using monoclonal antibody to CD68. Statistical analyses were carried 
out using SPSS13.0.
Results: 
(1) Macrophage counts in tumor stromal and islets in lung cancer were 
signiﬁcantly lower than those in benign lesions (p<0.05); Macro-
phage counts in tumor islets were signiﬁcantly lower than those in 
tumor stroma (p<0.05).
(2) Tumor islets macrophage counts and Tumor islets/stromal mac-
rophage ratio were both inversely correlated with tumor stages; 
Tumor stromal macrophage counts were positively correlated with 
tumor stages; Tumour islets macrophage counts in patients with 
lymph node metastasis were lower than those without lymph node 
metastasis(P<0.05). Tumor stromal macrophage counts in patients 
with lymph node metastasis were higher than those without lymph 
node metastasis(p>0.05).
(3) Tumor islets macrophage counts and tumor islet/stromal macro-
phage ratio were positively correlated with patient survival time 
(P<0.001); Tumor stromal macrophage counts were inversely cor-
related with patient survival time (P<0.01).
(4) Tumor islet macrophage counts and tumor islet/stromal macrophage 
ratio were favorable independent prognostic indicators(p<0.05);In 
contrast, tumor stromal macrophage count was an independent 
predictor of reduced survival(p<0.05).
Conclusions: 
(1) Tumor islet macrophage count and tumor islet/stromal macrophage 
ratio are powerful predictors of survival in lung cancer;This has 
important implications for adjuvant therapy after resection of lung 
cancer.
(2) Macrophage inﬁltrated within tumor of lung cancer may have dual 
functions. Macrophages entered tumor islets may have anti-tumor 
immune response; but those remained in stroma may potentially 
promote progression and metastasis of cancer.
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Expression of CN-II in non-small cell lung cancer and its clinical 
significance
Qu, Lili12 Liu, Xiaoqing12 Wang, Weixia12 Li, Xiaoyan12 Zheng, 
Xiaoling2 Li, Xiaobing2 Liu, Guangxian2 
1 Lung Cancer Department in Tumor Center of PLA, Beijing, China 2 
Affiliated 307 Hospital, Academy of Military Medical Sciences, Beijing, 
China 
Background: Cytosolic 5-nucleotidase(CN-II), a nucleotide kinase, 
possesses both 5-nucleotidase and nucleoside phosphotransferase 
activities. Abnormal expression of CN-II may be correlated with 
resistance to nucleoside analogues anticancer drugs. This study was de-
signed to investigate the expression of CN-II in human non-small cell 
lung cancer (NSCLC) tissues and its correlation to clinic pathological 
parameters as well as prognosis in patients treated with gemcitabine. 
Methods: Expression of CN-II was detected in 70 cases of parafﬁn 
embedded NSCLC samples by immunohistochemistry. Its correlations 
to clinic pathological parameters as well as response to gemcitabine 
chemotherapy were analyzed using chi-square test. Log-ranl test was 
used to check wether CN-II expression was correlated with patients’ 
overall survival (OS). 
Results: The positive rate of CN-II in 70 non-small cell lung cancer tis-
sues were 52.9%. There was no signiﬁcant relationship between CN-II 
expression and clinic pathological parameters. Among 21 patients who 
had received gemcitabine chemotherapy, those with tumor progressed 
(positive rate 83.3%) had higher CN-II expression than the patients 
with efﬁcacious (positive rate16.7%, P<0.05) and disease control che-
motherapy (positive rate33.3%, P<0.05). Patients with positive CN-II 
expression had signiﬁcant better OS than negative (P<0.05). 
Conclusion: Over expression of CN-II maybe correlated with resis-
tance to gemcitabine. CN-II may be an independent prognostic factor 
for response and total survival time for patients with gemcitabine 
chemotherapy. 
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Increased expression levels of human telomerase reverse 
transcriptase (hTERT) mRNA correlates with poor prognosis in 
resected non small cell lung cancer (NSCLC) patients
López Vivanco, Guillermo1 Carrera Revilla, Sergio1 Muñoz Llarena, 
Alberto1 Rubio Etxebarria, Itziar1 Mañé Martínez, Joan Manel1 Calvo 
Martínez, Begoña2 Aresti, Unai2 Jangi, Muhialdin S.2 Gil-Negrete-
Laborda, Aitziber1 Ancizar Lizarraga, Nerea1 
1 Medical Oncology Department, Hospital Cruces, Barakalado, Spain 2 
Molecular Biology Laboratory, Investigational Unit, Hospital Cruces, 
Barakalado, Spain 
Background: Lung cancer is the leading cause death worldwide. 
NSCLC accounts for approximately 80% of all lung tumors. Telom-
erase adds hexameric TTAGGG nucleotide repeats onto the ends of 
chromosomal DNAs to compensate for losses of each cell replication. 
Correlation between telomerase level expression, clinico-pathological 
characteristics and survival of lung cancer is not well established in 
NSCLC.
Methods: We studied 149 consecutive patients (140 men/9 women) 
with resected NSCLC: 37.6% adenocarcinoma, 59 % squamous cell, 
and 3.4% large cell carcinoma. Pathological stage: I (36.9%), II (32.3%) 
and III (30.8%). Reverse transcription-polymerase chain reaction (RT-
PCR) analysis was used for the detection hTERT expression in lung 
cancer tissues immediately snap-frozen in liquid nitrogen at -80 ºC.
Results: Median and mean values of hTERT mRNA were 18.27 and 
475.29 (SE 309.76). There were no signiﬁcant differences on expres-
sion according to sex, histology, smoking history and pathological 
stage (ANOVA). Patients with highest values of hTERT mRNA expres-
sion (percentile 95, cut-off value >353) had worse median progression 
free survival (PFS) (p=0.024) and overall survival (OS) (p=0.020), 
using Kaplan-Meier method. Multivariate analysis by Cox regression 
yielded that hTERT level > 353 independently predicted a worse PFS 
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(HR=0.39; 95% CI 0.17-0.93, p=0.034) and OS (HR=0.32; 95% CI 
0.12-0.82, p=0.017). 
Conclusions: A high level of telomerase expression in tumoral tissue 
is strongly associated with increased risk of recurrence and mortal-
ity in resected NSCLC. The level of hTERT mRNA would predict the 
prognosis of lung cancer patients. 
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Prognostic value of atelectasis for locally advanced non-small cell 
lung cancer (NSCLC)
Dediu, Mircea; Median, Mircea Dragos; Anghel, Rodica; Gal, Cristian 
Ervin; Alexandru, Aurelia 
“Prof. Dr. Al. Trestioreanu”, Institute of Oncology, Bucharest, Romania
Purpose: According to the TNM staging system, atelectasis (At) is 
considered a bad prognostic factor within the T category. According 
to our clinical experience we intuitively considered the opposite. The 
aim of the study was to evaluate the inﬂuence of atelectasis on patient 
outcome for unresectable stage III and IV (NSCLC).
Patients and Methods: We prospectively evaluated the median 
progression free (PFS) and overall survival (MS), for the patients with 
pathologically/ citologically proven NSCLC, in relation with the pres-
ence or absence of the atelectasis. The treatment consisted of sequential 
chemo-radiation for stage III and platinum based combination chemo-
therapy with palliative irradiation for stage IV (PS:0-1). A preplanned 
analysis according to stage was foreseen.
Results: a number of 1352 consecutively treated patients, during 
1997-2004, were evaluated. Overall, we identiﬁed a number of 68 (5%) 
patients with atelectasis, 46/592 patients with stage III and 22/760 stage 
IV, ratio sex M/F: 1108 (82%)/172 (17.5%), age range 23-82 (median 
age 57 years), histology: adenocarcinoma: 419 (31%), squamous cell: 
327 (24%), undifferentiated: 127 (9.5%), other types: 31 (2.5%) and 
cytology: 448 (33%).
The median PFS and OS for patients with and without atelectasis are 
presented in table below. 
  No. Pat. PFS (m) p OS (m) p 2ys Sv
   95% CI  95% CI   
St III (592) At + 46 19 .0001 24 .0001 57%
(43.7%)   (11.22-25.78)  (18.65-29.35)   
 At - 546 8  14  13.5%
   (6.98-9.02)  (12.43-15.57)   
St IV (760) At + 22 8 .1046 16 .1451 19%
(56.3%)   (5.80-10.20)  (4.49-27.51)   
 At - 738 6  9  4%
   (5.53 -6.47)  (8.61-9.39)   
Total At + 68 16 <.0001 21  38%
   (11.19-20.81)  (12.37-29.63)   
 At - 1284 7  10  9.5%
   (6.53-7.47)  (9.48-10.52)   
Conclusion: Atelectasis predicts for better PFS and OS in patients with 
advanced NSCLC. The subset analysis showed a statistically signiﬁcant 
improved PFS and OS for unresectable stage III. For stage IV there is 
also a trend towards improved survival but statistically not signiﬁcant. 
The biologic impact of this clinical aspect in NSCLC should be further 
evaluated.
The multivariate analysis (including, age, sex, histology, RT, stage, 
type of chemotherapy) showed a statistically signiﬁcant independent 
prognostic value for atelectasis for stage III, but not in stage IV.
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Aberrant methylation of RASSF1A in small-sized lung 
adenocarcinoma and its relationship to clinicopathological features
Miyajima, Kuniharu1 Saji, Hisashi1 Tsuboi, Masahiro1 Hirano, Takashi1 
Kato, Harubumi1 Suzuki, Makoto2 Shigematsu, Hisayuki2 Maruyama, 
Riichiro2 Toyooka, Shinichi2 Gazdar, Adi F.2 
1 Tokyo Medical University, Tokyo, Japan 2 University of Texas South-
western Medical Center, Dallas, TX, USA 
Purpose: Aberrant methylation of CpG islands in promoter regions 
of tumor cells is one of the major mechanisms for silencing of tumor 
suppressor genes. Chromosome 3p is deleted frequently in lung cancer. 
The RAS association domain family 1A (RASSF1A) gene was isolated 
from the 3p21.3 region homozygously deleted in lung cancer cell lines, 
and it was shown to be inactivated by hypermethylation of the promoter 
region in lung cancers. In this study, we investigated the clinicopatho-
logical signiﬁcances of RASSF1A methylation in the development and/
or progression of small-sized (less than 2.0cm) lung adenocarcinoma. It 
is important to identify a marker for high-risk early stage patients who 
should beneﬁt from new investigational adjuvant therapies.
Methods: Surgically resected specimens from 260 primary lung adeno-
carcinoma 77 cases of small-sized adenocarcinoma. We determined the 
frequency of aberrant promoter methylation of the RASSF1A genes in 
77 small-sized lung adenocarcinoma. Aberrant promoter methylation 
was examined using methylation-speciﬁc PCR (MSP).
Results: Twenty-ﬁve of 77 (32.5%) tumors showed RASSF1A 
methylation. RASSF1A methylation was dominantly detected in 
smoker (p<0.03). There was no signiﬁcant correlation of RASSF1A 
methylation with gender, age, T stage, N stage and pathological stage. 
RASSF1A methylation correlated with adverse survival by univari-
ate analysis (p<0.005; log-rank test) as well as multivariate analysis 
(p=0.0062; risk ratio 4.251; 95% conﬁdence interval, 1.507-11.993). 
Furthermore, RASSF1A promoter hypermethylation in resected stage I 
small-sized lung adenocarcinoma was associated with impaired patient 
survival (p<0.01).
Conclusion: Aberrant promoter methylation of the RASSF1A was 
present in 25 of 77 (32.5%) of small-sized lung adenocarcinoma by 
MSP assay. These results indicated that epigenetic inactivation of 
RASSF1A plays an important role in the progression of small-sized 
lung adenocarcinoma, and that RASSF1A hypermethylation appears to 
be a useful molecular marker for the prognosis of patients with small-
sized and stage I lung adenocarcinoma.
Clinical Implications: RASSF1A is a potential tumor suppressor gene 
that undergoes epigenetic inactivation in lung adenocarcinoma through 
hypermethylation of its promoter region. RASSF1A methylation was 
signiﬁcantly related to unfavorable prognosis in small-sized lung 
adenocarcinoma.
